These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27113114)

  • 1. Long-Term PPI Use: Balancing Potential Harms and Documented Benefits.
    Laine L; Nagar A
    Am J Gastroenterol; 2016 Jul; 111(7):913-5. PubMed ID: 27113114
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proton pump inhibitors, a family of drugs in continuous expansion].
    Pellicano R
    Minerva Gastroenterol Dietol; 2000 Dec; 46(4):231-41. PubMed ID: 19320085
    [No Abstract]   [Full Text] [Related]  

  • 3. Ask the doctor. Do PPI drugs for stomach acid reduce the risk of cancer in people (like me) with Barrett's esophagus?
    Komaroff AL
    Harv Health Lett; 2014 Apr; 39(6):2. PubMed ID: 24873004
    [No Abstract]   [Full Text] [Related]  

  • 4. Proton pump inhibitors: the good, the bad, and the unwanted.
    Chubineh S; Birk J
    South Med J; 2012 Nov; 105(11):613-8. PubMed ID: 23128806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of Barrett's esophagus: can it prevent cancer?
    Sampliner RE
    Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing the risks and benefits of proton pump inhibitors.
    Gill JM; Player MS; Metz DC
    Ann Fam Med; 2011; 9(3):200-2. PubMed ID: 21555747
    [No Abstract]   [Full Text] [Related]  

  • 8. [Barrett esophagus: modern diagnosis, drug therapy and reduce risk of cancer].
    Kashin SV; Ivanikov IO
    Eksp Klin Gastroenterol; 2009; (2):90-8. PubMed ID: 19552026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gastroesophageal reflux disease and dyspepsia--drug therapy].
    Gräter H
    Praxis (Bern 1994); 2006 Aug; 95(31-32):1179-83. PubMed ID: 16909686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
    Pallotta S; Pace F; Marelli S
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):509-22. PubMed ID: 19072398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: the effects of overlapping symptoms on the response to PPI therapy in GERD.
    Kennedy M; Ford AC
    Aliment Pharmacol Ther; 2012 Jul; 36(2):207; author 207-8. PubMed ID: 22703466
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of pantoprazole in the therapy of esophageal reflux disease].
    Lazebnik LB; Vasil'ev IuV
    Eksp Klin Gastroenterol; 2008; (2):102-4. PubMed ID: 19145874
    [No Abstract]   [Full Text] [Related]  

  • 14. A 59-year-old woman with gastroesophageal reflux disease and barrett esophagus, 4 years later.
    Burns RB
    JAMA; 2006 Nov; 296(17):2140. PubMed ID: 17077379
    [No Abstract]   [Full Text] [Related]  

  • 15. Dyspepsia and reflux in primary care: rough DIAMOND of a trial.
    van Zanten SV
    Lancet; 2009 Jan; 373(9659):187-8. PubMed ID: 19150689
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Esophagogastroduodenoscopy Surveillance for Patients with Barrett Esophagus.
    Palamara K
    Med Clin North Am; 2016 Sep; 100(5):1057-64. PubMed ID: 27542425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
    van der Velden AW; de Wit NJ; Quartero AO; Grobbee DE; Numans ME
    Digestion; 2013; 87(2):85-90. PubMed ID: 23364219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal.
    Savarino V; Dulbecco P; de Bortoli N; Ottonello A; Savarino E
    Eur J Intern Med; 2017 Jan; 37():19-24. PubMed ID: 27784575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
    Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
    Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.